ChemSpider 2D Image | Trelagliptin succinate | C22H26FN5O6

Trelagliptin succinate

  • Molecular FormulaC22H26FN5O6
  • Average mass475.470 Da
  • Monoisotopic mass475.186707 Da
  • ChemSpider ID26286875

  • defined stereocentres - 1 of 1 defined stereocentres

More details:

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

Trelagliptin succinate [USAN]
1029877-94-8 [RN]
2-({[6-[(3R)-3-aminopipidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)- yl}methyl)-4-fluorobenzonitrile hydrogen butanedioate
2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)-4-fluorobenzonitrile; butanedioic acid
Acide succinique - 2-({6-[(3R)-3-amino-1-pipéridinyl]-3-méthyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl}méthyl)-4-fluorobenzonitrile (1:1) [French] [ACD/IUPAC Name]
Benzonitrile, 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-4-fluoro-, butanedioate (1:1) [ACD/Index Name]
Bernsteinsäure --2-({6-[(3R)-3-amino-1-piperidinyl]-3-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl}methyl)-4-fluorbenzonitril (1:1) [German] [ACD/IUPAC Name]
Succinic acid - 2-({6-[(3R)-3-amino-1-piperidinyl]-3-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl}methyl)-4-fluorobenzonitrile (1:1) [ACD/IUPAC Name]
SYR111472 Succinate
Zafatek [Trade name]
More...

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

SYR-472 [DBID]
PubChem Substance ID 329825761 [DBID]
  • Experimental Physico-chemical Properties
  • Miscellaneous

    • Bio Activity:

      DPP4 MedChem Express HY-15408A
      Metabolism/Protease; MedChem Express HY-15408A
      Trelagliptin(SYR-472) is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D). MedChem Express http://www.medchemexpress.com/e-3810.html
      Trelagliptin(SYR-472) is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D). ;IC50 value:;Target: DPP4;Two Phase II clinical studies have been completed with Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus. Phase III clinical studies with trelagliptin in Japan to evaluate its safety and efficacy in a once-weekly oral treatment regimen. Currently, all available DPP-4 inhibitors are dosed once-daily. A once-weekly treatment, such as trelagliptin, would provide patients with a convenient treatment alternative and has the potential to improve treatment compliance. MedChem Express HY-15408A

Predicted data is generated using the ACD/Labs Percepta Platform - PhysChem Module, version: 14.00

No predicted properties have been calculated for this compound.

Click to predict properties on the Chemicalize site


Advertisement